Aileen L. Pangan

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Silvio Danese, Séverine Vermeire, Wen Zhou et al. · The Lancet · 2022 · 597 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +10

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 543 citations

Life Sciences, Dermatology, Pharmacotherapy +13

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

Joachim Sieper, Désirée van der Heijde, Maxime Dougados et al. · Annals of the Rheumatic Diseases · 2012 · 532 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Mark C. Genovese, Roy Fleischmann, Bernard Combe et al. · The Lancet · 2018 · 443 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Roy Fleischmann, Aileen L. Pangan, In‐Ho Song et al. · Arthritis & Rheumatology · 2019 · 436 citations

Medicine, Pharmacology, Pharmacotherapy +16